KẾT QUẢ TRUYỀN KHỐI TIỂU CẦU Ở MỘT SỐ NHÓM BỆNH NHI TẠI VIỆN HUYẾT HỌC – TRUYỀN MÁU TRUNG ƯƠNG 2024-2025

Abstract

Introduction: The outcomes of platelet transfusion in pediatric patients are less studied compared to adults, despite significant differences in disease characteristics and biometric features between the two groups. Objective: To describe the results of platelet transfusion in pediatric patients with hematologic disorders, including primary immune thrombocytopenia, acute leukemia, and bone marrow failure. Subjects: The study included 267 pediatric patients who received platelet transfusion, comprising 113 patients with acute leukemia, 135 patients with primary immune thrombocytopenia, and 19 patients with bone marrow failure at the National Institute of Haematology - Blood Transfusion from March 2024 to March 2025. Methods: A cross-sectional study, selecting patients for platelet transfusion and monitoring them before and 24 hours after transfusion to evaluate the outcomes. Results: A total of 268 platelet transfusions were administered to 267 patients. The results showed that all patients exhibited cessation of clinical hemorrhagic symptoms. The average increase in platelet count post-transfusion was 39.5 G/L. The mean Corrected Count Increment (CCI) at 24 hours was 21.6, and the mean Post-Platelet Recovery (PPR) was 35.3%. The proportion of patients with a CCI > 4.5 at 24 hours was 84.6%, while 47.6% achieved a PPR > 30%. Conclusion: Platelet transfusion is an effective intervention for increasing platelet count and reducing hemorrhagic complications in patients with hematologic disorders. Patients with a CCI < 4.5 at 24 hours should undergo further investigation to evaluate and identify underlying causes.